Pharmaceutical giant Bayer has announced plans to buy 100 percent of Germany-based private pharmaceutical conglomerate Steigerwalk Arzneimittelwerk. Financial details of the deal were not released in a press release; the parties expect to close the deal by July 2013, though it remains subject to approval by antitrust regulators. According to Bayer, the move is part of a larger agenda to promote “organic growth” and expand its product offering for consumers. According to a press release, the move will also expand business for Bayer throughout Germany and east-central Europe.
Featured News
White House, GOP Again Trying to Enact Federal Preemption of State AI Laws
Mar 17, 2026 by
CPI
Klobuchar Unveils Bill to Strengthen Court Oversight of Antitrust Settlements
Mar 17, 2026 by
CPI
More Than 20 States Now Have Privacy Laws. Is Your Company Keeping Up?
Mar 17, 2026 by
CPI
Google Seeks to Buy Liquid Cooling Technology Amid AI Data Centre Boom
Mar 17, 2026 by
CPI
Mastercard to Acquire BVNK in $1.8 Billion Deal to Expand Stablecoin Capabilities
Mar 17, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece